Telesis Bio Statistics
Total Valuation
Telesis Bio has a market cap or net worth of 21,622. The enterprise value is 42.89 million.
| Market Cap | 21,622 |
| Enterprise Value | 42.89M |
Important Dates
The last earnings date was Thursday, August 7, 2025.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Telesis Bio has 1.80 million shares outstanding.
| Current Share Class | 1.80M |
| Shares Outstanding | 1.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +2.45% |
| Owned by Insiders (%) | 19.85% |
| Owned by Institutions (%) | 0.51% |
| Float | 768,461 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | 0.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.90 |
| EV / Sales | 2.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.80 |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 4.21.
| Current Ratio | 1.23 |
| Quick Ratio | 0.87 |
| Debt / Equity | 4.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.68 |
| Interest Coverage | -26.84 |
Financial Efficiency
Return on equity (ROE) is -178.99% and return on invested capital (ROIC) is -33.51%.
| Return on Equity (ROE) | -178.99% |
| Return on Assets (ROA) | -30.10% |
| Return on Invested Capital (ROIC) | -33.51% |
| Return on Capital Employed (ROCE) | -172.55% |
| Revenue Per Employee | 436,769 |
| Profits Per Employee | -1.23M |
| Employee Count | 147 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 3.37 |
Taxes
In the past 12 months, Telesis Bio has paid 7,000 in taxes.
| Income Tax | 7,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.20% in the last 52 weeks. The beta is 2.73, so Telesis Bio's price volatility has been higher than the market average.
| Beta (5Y) | 2.73 |
| 52-Week Price Change | -99.20% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.20 |
| Relative Strength Index (RSI) | 51.96 |
| Average Volume (20 Days) | 60 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.49 |
Income Statement
In the last 12 months, Telesis Bio had revenue of 17.03 million and -47.93 million in losses. Loss per share was -28.02.
| Revenue | 17.03M |
| Gross Profit | 7.98M |
| Operating Income | -31.25M |
| Pretax Income | -45.07M |
| Net Income | -47.93M |
| EBITDA | -28.69M |
| EBIT | -31.25M |
| Loss Per Share | -28.02 |
Balance Sheet
The company has 4.51 million in cash and 16.29 million in debt, giving a net cash position of -11.78 million or -6.54 per share.
| Cash & Cash Equivalents | 4.51M |
| Total Debt | 16.29M |
| Net Cash | -11.78M |
| Net Cash Per Share | -6.54 |
| Equity (Book Value) | 3.87M |
| Book Value Per Share | -15.35 |
| Working Capital | 1.49M |
Cash Flow
In the last 12 months, operating cash flow was -22.87 million and capital expenditures -992,000, giving a free cash flow of -23.86 million.
| Operating Cash Flow | -22.87M |
| Capital Expenditures | -992,000 |
| Free Cash Flow | -23.86M |
| FCF Per Share | -13.24 |
Margins
Gross margin is 46.87%, with operating and profit margins of -183.44% and -267.41%.
| Gross Margin | 46.87% |
| Operating Margin | -183.44% |
| Pretax Margin | -264.56% |
| Profit Margin | -267.41% |
| EBITDA Margin | -168.42% |
| EBIT Margin | -183.44% |
| FCF Margin | n/a |
Dividends & Yields
Telesis Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.53% |
| Shareholder Yield | -3.53% |
| Earnings Yield | -221,653.87% |
| FCF Yield | -110,359.82% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 9, 2024. It was a reverse split with a ratio of 0.0555556.
| Last Split Date | May 9, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0555556 |
Scores
Telesis Bio has an Altman Z-Score of -13.79 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.79 |
| Piotroski F-Score | 2 |